UK Health Bill: Three Amendments Tabled in Parliament to Enable a Future Medical Device Licensing Regime

Key Points

On 1 September 2026, the UK Government tabled three amendments to the Health Bill, and the Medicines and Healthcare products Regulatory Agency (MHRA) published a corresponding explanatory note.

• Information-sharing powers: clearer legal authority for MHRA to share specified medicines and medical device information with trusted UK government bodies and global regulatory partners.
• Mechanism for updating regulations: allowing legislation to reflect subsequent updates to technical standards and international guidance, with more proportionate consultation arrangements.
• Enabling power for a future device licensing regime: devices entering the Great Britain market through a UK domestic route may in future require an MHRA-issued licence rather than relying solely on third-party conformity assessment.

The amendments themselves do not produce any regulatory change that takes effect immediately. They still require policy design, public consultation, impact assessment and parliamentary scrutiny. During the transition, the UKCA regime remains in place, and Northern Ireland continues to apply EU MDR and EU IVDR.

Source and Scope Notes

Source organisations: Medicines and Healthcare products Regulatory Agency (MHRA); UK Government - Medical devices: EU regulations for MDR and IVDR

Original publication date: 1 September 2026

Verification and access date: 27 September 2026

Sources: Medicines and Healthcare products Regulatory Agency (MHRA); UK Government - Medical devices: EU regulations for MDR and IVDR

MHRA: https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill (1 September 2026)

UK Government - Medical devices: EU regulations for MDR and IVDR: https://www.gov.uk/guidance/medical-devices-eu-regulations-for-mdr-and-ivdr

Full Translated Core Content

Event: Three Amendments Enter the Parliamentary Process

On 1 September 2026, the UK Government tabled three amendments to the Health Bill, aimed at making the legislation governing medicines and medical devices easier to update as science and technology evolve. The Medicines and Healthcare products Regulatory Agency (MHRA) published a corresponding explanatory note on its website.

The three amendments relate respectively to information-sharing powers, a mechanism for updating regulations, and an enabling power for a future medical device licensing regime.

It is important to establish the boundaries first: the amendments themselves do not create any regulatory requirement that takes effect immediately. The official text states that these measures still require further policy design, public consultation and parliamentary scrutiny before they can actually be implemented. The current stage is the laying down of legislative enabling powers, not the starting point of rule enforcement.

Amendment One: Information-Sharing Powers

The amendment would give MHRA clearer legal powers to share specified information on medicines and medical devices with trusted UK government bodies and global regulatory partners, where this supports public health, patient safety, access to innovation and effective regulation.

The official note also emphasises that existing safeguards remain unchanged: information sharing remains subject to statutory standards and the principle of proportionality; commercially sensitive information and patient information continue to be protected by a range of measures, including data protection legislation and patient consent.

Amendment Two: Mechanism for Updating Regulations

This amendment addresses the speed at which regulations can be updated. The proposal would allow legislation to automatically reflect subsequent updates to documents such as technical standards and international guidelines, so that rules can keep pace with change.

It also proposes more proportionate consultation arrangements: minor changes could be handled through targeted engagement, while major policy reforms would still require full public consultation.

The proposal would additionally allow certain technical, administrative or minor regulatory adjustments to become part of legislation directly, unless Parliament objects.

Amendment Three: Future Medical Device Licensing Power

The third amendment provides the authority to establish a medical device licensing regime in the future. It would amend the Medicines and Medical Devices Act 2021 to create the legal basis for a subsequent device licensing framework; that framework would still be subject to policy design, public consultation, impact assessment and parliamentary scrutiny.

The direction being explored officially is that medical devices entering the Great Britain market through a UK domestic route may in future need to obtain a licence issued by MHRA, rather than relying solely on third-party conformity assessment. Any future regime would be designed proportionately to risk, with different levels of scrutiny applying to different products.

The official note further states that these licensing powers are intended to support a more modern and more adaptable regulatory framework, in response to the changes brought by software and artificial intelligence based medical devices.

What Is Not Yet Settled

The following points are explicitly stated in the original text and are pending rather than settled. The amendments do not change current requirements, and any measure requires further development and consultation. While the future device licensing model takes shape, the UKCA regime continues to apply in the Great Britain market. There is no change to the policy intent on international reliance and recognition.

Under the Windsor Framework, Northern Ireland continues to apply the EU Medical Devices Regulation (EU MDR) and the EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR), in order to maintain its dual access to the EU single market and the UK internal market.

Scope of Application

This article discusses changes at the level of the UK legislative process. It is relevant to device companies planning to enter the Great Britain market through a UK domestic route, and to global manufacturers tracking the direction of UK regulation. The Northern Ireland route and the application of EU regulations are not affected by the content of these amendments.

Source and Verification Notes

Source: MHRA website news item, MHRA regulatory reform amendments tabled in Government's Health Bill, published 1 September 2026. Link: https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill

Supplementary source: UK Government guidance page on medical devices (EU MDR/IVDR), used to verify the statement that Northern Ireland applies EU regulations: https://www.gov.uk/guidance/medical-devices-eu-regulations-for-mdr-and-ivdr

Verification scope and access date: Both gov.uk pages above were accessed to verify the three directions of the amendments, the statement that no change takes effect immediately, the continuation of UKCA, the unchanged policy on international reliance and recognition, and the statement that Northern Ireland continues to apply EU MDR/IVDR. Access date: 27 September 2026.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The official text prevails, and the content may change with subsequent official updates.

AIMEILI Regulatory Interpretation and Business Impact

What This Development Means for Medical Device Companies

For updates of this kind issued by the Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Government, companies should first determine whether the information concerns regulatory policy, guidance and standards, recalls and safety, product performance, quality systems, or post-market surveillance. Different types of information affect the registration pathway, technical documentation, labelling and instructions for use, risk management and market maintenance in different ways, and should not be treated simply as general industry news.

For medical device companies, the priority is to convert the news into executable compliance actions: confirm whether the change concerns the same type of product, the same technology route or the same risk area; check whether existing documentation still supports the requirements of the target market; and where necessary update risk management, performance verification, clinical evaluation, labelling and instructions for use, distributor communications and post-market surveillance records.

Which Documents Should Companies Review First

Priority should be given to reviewing the intended purpose of the product, the basis for classification, ISO 13485 quality system evidence, risk management files, performance verification data, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents and existing registration certificates.

Common Risks

Common risks include unclear classification decisions, an incomplete evidence chain across documents, labelling and instructions for use that have not been localised, unclear responsibilities of the authorised representative, and insufficient arrangements for post-market maintenance.

AIMEILI View: How to Read These Amendments

For device companies already active in, or planning to enter, the UK market, the value of these amendments lies not in what must be done today, but in how the pathway may develop in future. The official position is explicit that there is no immediate change, but one of the three enabling powers points directly at device market access: products entering the Great Britain market through a UK domestic route may in future require an MHRA-issued licence, rather than relying solely on third-party conformity assessment. That is not a rule today, but it is a policy direction.

Short-Term Actions

Maintain the current compliance rhythm. Do not pause ongoing UKCA-related preparation because of legislative news; the official note states that the UKCA regime remains valid during the transition period. Record this development in the mid-term plan for the UK market: if a company currently relies on a notified body for conformity assessment, it should allow for the possibility of dealing directly with MHRA in future, including application procedures, depth of review and time costs. At the same time, establish regular tracking of the UK parliamentary process, because the subsequent policy design, public consultation and impact assessment are what will determine the actual threshold.

Medium-Term Preparation

From a product perspective, software and artificial intelligence based devices were named officially as part of the background driving this round of reform. Companies in these areas are well placed to review in advance their technical documentation, algorithm change management and existing evidence chains for post-market performance monitoring, because once a licensing regime introduces different levels of scrutiny, the completeness of evidence will directly affect review costs.

From a systems perspective, the other side of making regulation easier to update is that changes to standards and international guidance will enter legal texts more quickly. Companies need a regulatory intelligence mechanism capable of keeping pace with standards updates, rather than discovering changed requirements only at an annual review.

Relationship with Existing Pathways

Products that already hold UKCA or CE marking and have completed conformity assessment through a notified body can continue to supply the Great Britain market under current requirements during the transition period. These amendments do not change the validity of UKCA, nor do they change the established UK policy on international reliance and recognition.

What genuinely needs reassessment is market entry planning on a cycle of two years or more: if the UK is a priority market, incorporating the potential review costs of a licensing regime into budgets and timelines now will be more manageable than adjusting at short notice after the regime is in place.

For companies serving both the UK and EU markets, it is advisable to manage the UK domestic route and the Northern Ireland route separately. Northern Ireland continues to apply EU MDR/IVDR, and while the technical documentation and compliance evidence for the two routes overlap, they are not fully equivalent. Mixing them in a single project plan tends to create duplicated work later. Setting out clearly the differences and the shared elements between the two routes is a low-cost preparation for future policy change.

Boundaries of Applicability

The above is a directional assessment, not a registration conclusion. The amendments still require parliamentary scrutiny, the licensing regime remains at the enabling stage, and the specific design, timetable and scope of application are undetermined. The current position whereby Northern Ireland applies EU regulations is unaffected, and companies using the Northern Ireland route should assess their products under EU MDR/IVDR. The market access pathway for any specific product must be confirmed against the official text and subsequent formal documents.

FAQ

Can the UK Health Bill amendments on a future medical device licensing regime be used directly as a basis for a regulatory submission?

No. This article is intended for preliminary understanding and project assessment. A formal submission must still be based on the latest requirements of the target country's regulatory authority, the concluded classification of the product, and the company's actual documentation. The amendments are an enabling measure only and do not constitute an approval pathway or submission basis at this stage.

What should companies do first after seeing an update of this kind?

Companies should begin with a documentation gap assessment to determine whether the update affects the registration pathway, technical documentation, labelling, quality system or post-market maintenance. Where the update touches on a product's intended purpose, classification or evidence requirements, the relevant files should be reviewed and, if necessary, updated in line with the target market's current rules. Where the update is a parliamentary or policy development with no immediate effect, it should be logged in the regulatory intelligence system and reflected in market entry planning.

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting judgement.

Applicability boundaries: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, test conclusions or legal advice.